Cancer Cell



Zetagen is committed to the treatment of metastatic cancer lesions to bone and other soft tissue organs Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone. When these cancers relocate, they can cause changes to the bone, damaging it in a process called osteolysis. Osteolysis can cause small holes within the bone, weakening it and increasing the risk of breakage. These holes are called “lytic lesions.” Among cancers which metastasize to bone, Breast and Prostate are most prevalent, amounting to approximately 70-percent of cases.[1]
Lytic lesions can cause severe, debilitating pain in patients with advanced cancer. Patients with these lesions often experience a reduced quality of life with multiple skeletal-related events (SREs), including fractures, spinal cord compression, elevated levels of calcium in the blood or “hypercalcaemia”, bone marrow infiltration and severe bone pain.[2] Bone metastases are also a major cause for morbidity in patients with advanced stage cancer.[3]

Our product, ZetaMet™ has thus far demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain, and stimulate targeted bone regeneration.
[1] Li S, Peng Y, Weinhandl ED, et al. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012;4:87-93. doi:10.2147/CLEP.S28339
[2] Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett. 2013;6(2):306-310. doi:10.3892/ol.2013.1372
[3] Cecchini M, Wetterwald A, Pluijm G, Thalmann G. Molecular and biological mechanisms of bone metastasis. EAU Update Series 2005;3:214-26. [Google Scholar]


ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone. The U.S. Food and Drug Administration recently awarded ZetaMet™ Breakthrough Device Designation for the treatment of metastatic bone cancer. Currently, ZetaMet™ has been approved by Health Canada for a clinical trial which is currently enrolling for the treatment of metastatic breast cancer lesions to the spine. Also, ZetaFuse® has been approved by the Human Research Ethics Committee in Australia for the treatment of Degenerative Disc Disease for the fusion of the cervical spine.


ZetaMet-P™ is a synthetic, small-molecule, antitumorigenic biologic technology being developed to target and resolve metastatic prostate cancer bone lesions while inhibiting future tumor growth. ZetaMet-P™ is administered via an outpatient percutaneous procedure directly to the lesion site. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic prostate cancer bone lesions.


ZetaMAST™ is a novel drug being designed for patients with unresectable, multifocal breast cancer metastases to the liver, lung, or brain. ZetaMAST™ can be administered as a single, percutaneous injection utilizing a proprietary hydrogel carrier containing a precise, tailored concentration of our small molecule. Preclinical studies have demonstrated ZetaMAST™ may cease lesion growth, with the goal of enabling improved quality of life as part of a cancer treatment program, including longevity.

ZetaOnc™ Settable

ZetaOnc™ Settable is the Next Generation Bone Cement which will provide significant benefits to clinicians treating patients with imminent risk of Skeletal Related Event (SRE) / fracture of the vertebral body or bone contributed from a metastatic lytic lesion. ZetaOnc™ is resorbable, antitumorigenic, osteoinductive, hemostatic and has the same modulus of elasticity as healthy bone. It has a superior safety profile (e.g., no toxicity and material curing is isothermic). ZetaOnc™ Settable is made possible by the discovery of a NEW chemical entity coupled with Zetagen’s existing bone healing product that is focused on delivering a well-known small molecule to the wound site via a proprietary biologic carrier. ZetaOnc™ will integrate with adjacent bone, grow new bone, inhibit future tumor growth, and once healed will not cause an adjacent fracture.